CLINICAL TRIALS PROFILE FOR ARIXTRA
✉ Email this page to a colleague
All Clinical Trials for ARIXTRA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00060554 ↗ | A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN) | Withdrawn | Schering-Plough | Phase 2 | 2003-04-01 | The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting. |
NCT00256100 ↗ | Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure. | Terminated | Melbourne Health | N/A | 2004-06-01 | The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new drug to prevent blood clotting in the continuous dialysis machine used in intensive care patients who have kidney failure. |
NCT00328939 ↗ | ARIXTRA Local Study For Registration In China. | Completed | GlaxoSmithKline | Phase 3 | 2004-05-01 | This is a local registration study in China to compare the safety and efficacy of ARIXTRA to Enoxaparine in patients undergoing elective major hip or knee replacement or a revision of components. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ARIXTRA
Condition Name
Clinical Trial Locations for ARIXTRA
Trials by Country
Clinical Trial Progress for ARIXTRA
Clinical Trial Phase
Clinical Trial Sponsors for ARIXTRA
Sponsor Name